Bermejo-Pérez M J, Villar-Chamorro E, Lemos-Simosomo M, García-González C, Galeote-Miguel A M
Hospital Regional Carlos Haya, Málaga, Spain.
An Sist Sanit Navar. 2011 May-Aug;34(2):307-10. doi: 10.4321/s1137-66272011000200018.
The management of patients with disseminated disease is a difficult problem. There is currently no consensus on the standard first-line treatment for metastatic melanoma. We present a case because of his exceptional evolution.
A 43 year old male diagnosed in 1999 with malignant melanoma stage IIA. In May 2000 hepatic and splenic metastases were detected. He received 6 cycles of biochemotherapy (cisplatin and DTIC, plus interleukin-2 and interferon-α) and another 6 cycles with single immunotherapy (interleukin-2 and interferon-α). Today, the patient is still alive and without evidence of disease.
Metastatic cutaneous melanoma, sometimes presents an unusual, favourable evolution. In the near future, the methods of detection of molecular markers are expected to identify factors involved in this type of response. Furthermore, new targeted therapies may become essential to maintain this positive trend.
